 |
|
As Founder and President of the Institute of Genomic medicine, a 501c3 Masschusetts Corporation with non-profit status, I have focused on how the new biological disciplines of genomics and proteomics may be combined with target-validation and computer-modeling strategies to provide enhanced value for the discovery of new drugs in the pharmaceutical industry. During the 1990s the Institute of Genomic Medicine worked closely with AlphaGene. |
|
 |